Amylyx Pharmaceuticals, Inc. AMLX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $27.61M+30.2% | $21.21M+6.8% | $19.86M-27.0% | $27.22M+23.0% | $22.12M-3.4% | ||
| $16.17M+5.0% | $15.39M-4.8% | $16.17M+3.4% | $15.64M-0.3% | $15.68M-8.3% | ||
| $43.78M+19.6% | $36.61M+1.6% | $36.03M-15.9% | $42.86M+13.4% | $37.8M-5.5% | ||
| -$43.78M-19.6% | -$36.61M-1.6% | -$36.03M+15.9% | -$42.86M-13.4% | -$37.8M+7.0% | ||
| $2.5M-31.7% | $3.65M+123% | $1.64M+16.1% | $1.41M-25.4% | $1.9M-23.3% | ||
| —— | -$32.95M+4.2% | -$34.39M+17.0% | -$41.44M-15.4% | -$35.91M+6.0% | ||
| —— | $46K— | $0— | $0— | $0+100% | ||
| -$41.28M-25.1% | -$33M+4.0% | -$34.39M+17.0% | -$41.44M-15.4% | -$35.91M+4.4% | ||
| -$0.37-32.1% | -$0.28+24.3% | -$0.37+19.6% | -$0.46-9.5% | -$0.42+22.2% | ||
| -$43.68M-19.7% | -$36.5M-1.6% | -$35.91M+15.9% | -$42.72M-13.5% | -$37.65M+7.0% | ||
| -$43.78M-19.6% | -$36.61M-1.6% | -$36.03M+15.9% | -$42.86M-13.4% | -$37.8M+7.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amylyx Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 100.0% and operating margin is -47349.8%, with a -45096.2% net margin.
- Where does Amylyx Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.